Last reviewed · How we verify
Urotol®
Urotol is a muscarinic receptor antagonist used to treat overactive bladder.
Urotol is a muscarinic receptor antagonist used to treat overactive bladder. Used for Symptomatic treatment of overactive bladder.
At a glance
| Generic name | Urotol® |
|---|---|
| Also known as | Tolterodine |
| Sponsor | R-Pharm |
| Drug class | Muscarinic receptor antagonist |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
It works by relaxing the bladder muscle and increasing bladder capacity, thereby reducing symptoms of overactive bladder such as urgency and frequency.
Approved indications
- Symptomatic treatment of overactive bladder
Common side effects
- Dry mouth
- Headache
- Dizziness
- Nausea
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urotol® CI brief — competitive landscape report
- Urotol® updates RSS · CI watch RSS
- R-Pharm portfolio CI